Crossmark

A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)

Crossref DOI link: https://doi.org/10.1186/s12882-024-03576-0

Published Online: 2024-08-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

C Willcocks, Lisa

Qian, Wendi

Cader, Ruzaika

Gatley, Katrina

Siddiqui, Hira

Tabebisong, Endurance

Champion, Karlena

Kronbichler, Andreas

Lightstone, Liz

Jayne, David

Wilson, Edward

Griffith, Megan
Funding

Funding for this research was provided by:

NIHR (17/83/06)
License Information

Text and Data Mining valid from 2024-08-07

Version of Record valid from 2024-08-07
More Information

Article History

Received: 28 March 2024

Accepted: 8 April 2024

First Online: 7 August 2024

Declarations

:

: The authors declare no competing interests.

: The sponsor is Cambridge University Hospital NHS Trust.

Document is current

Any future updates will be listed below